SCHEMBL4625467

SCHEMBL4625467

O=C(N[C@@H](Cc1ccc2nc(-c3c(Cl)cccc3Cl)ccc2c1)C(=O)O)c1cccc(C2CCNCC2)c1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 5/20 0.66
ITGAV P06756 2/20 0.66
ITGA4 P13612 4/20 0.47
ITGB7 P26010 4/20 0.47
ITGB3 P05106 5/20 0.42
ITGA2B P08514 5/20 0.42
PTPN1 P18031 2/20 0.41
ABL1 P00519 1/20 0.38
PIN1 Q13526 1/20 0.38
SCN3A Q9NY46 1/20 0.38
CA2 P00918 1/20 0.37
GSK3B P49841 1/20 0.37
DYRK1A Q13627 1/20 0.37
ITGB6 P18564 1/20 0.37
ALB P02768 1/20 0.37
IL2 P60568 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3312947 0.86 ITGB1 (0.67) ITGB1ITGAVITGA4ITGB7ITGB3
SCHEMBL4419511 0.85 ITGB1 (0.83) ITGB1ITGAVITGA4ITGB7ITGB3
SCHEMBL14302839 0.80 ITGB1 (0.60) ITGB1ITGAVITGA4ITGB7ITGB3
SCHEMBL3313356 0.80 ITGB1 (1.00) ITGB1ITGAVITGA4ITGB7
SCHEMBL3316398 0.80 ITGB1 (1.00) ITGB1ITGAVITGA4ITGB7
SCHEMBL3313373 0.80 ITGB1 (1.00) ITGB1ITGAVITGA4ITGB7
SCHEMBL8352229 0.80 ITGB1 (1.00) ITGB1ITGAVITGA4ITGB7
SCHEMBL3318272 0.79 ITGB1 (0.85) ITGB1ITGAVITGA4ITGB7
SCHEMBL8348741 0.78 ITGB1 (0.55) ITGB1ITGAVITGA4ITGB7ITGB3
SCHEMBL3314968 0.78 ITGB1 (0.87) ITGB1ITGAVITGA4ITGB7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501801-B1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES UCB PHARMA SA (BE) 2008-01-23 EP disclosed
EP-1870402-A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors UCB Pharma, S.A. (BE) 2007-12-26 EP disclosed